Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Pressure Builds On U.K. Government To Conclude Value-Based Pricing Deal With Industry

This article was originally published in The Pink Sheet Daily

Executive Summary

An influential parliamentary committee has called on the U.K. to reveal its plans for value-based pricing by the end of March so that companies, clinicians and patients can adjust to the change, which is expected to start in 2014.

You may also be interested in...



U.K. Value-Based Pricing Negotiations Could Help NICE-Rejected Cancer Drugs

Negotiations will start in September 2012 on a value-based pricing approach for new medicines in the U.K., and on a new PPRS scheme for currently marketed drugs, with a new suggestion: oncologics previously rejected by NICE might be reviewed again under the new VBP system.

Value-Based Pricing's Slow Progress In U.K. Worries Industry

With eighteen months until the start of a new drug pricing scheme, the slow progress and lack of detail on the U.K.'s value-based pricing (VBP) approach worries industry and suggests transitional arrangements may be necessary.

Merck KGaA Tightens Focus With Allergopharma Sale

Germany’s family-controlled big pharma, Merck KGaA, is divesting its allergens business, Allergopharma to the fast-growing Munich healthcare company, Dermapharm Holding.

 

Topics

UsernamePublicRestriction

Register

PS074772

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel